Summary: It is suggested that the bioavailability of CYP3A4 substrates might be low due toˆrst-pass metabolism in the small intestine, and it is possible that P-glycoprotein (P-gp) may in‰uenceˆrst-pass metabolism in a co-operative manner. We have collected information of the pharmacokinetics of CYP3A4 substrates to evaluate the fraction absorbed (Fa), intestinal availability (Fg) and hepatic availability (Fh) and have investigated the intestinalˆrst-pass metabolism and the eŠect of P-gp on this. The pharmacokinetic data involved ten compounds metabolized by CYP3A4 in humans, with and without an inhibitor or inducer. FaFg, which is the product of Fa and Fg, and Fh were calculated using three liver blood ‰ow rates (17.1, 21.4, 25.5 mL W min W kg) in consideration of variations in the liver ‰ow rate. Co-administration with an inhibitor of CYP3A4 and treatment of an inducer of CYP3A4 caused an increase and decrease in the FaFg of CYP3A4 substrates, regardless of the liver blood ‰ow, indicating that CYP3A4 substrates exhibit aˆrst-pass eŠect in their metabolism. This holds true regardless of whether the compounds are P-gp substrates or not. No relationship was observed between FaFg and Fh, regardless of the hepatic blood ‰ow rate and the P-gp substrates. The FaFg of both P-gp and non P-gp substrates decreased as the hepatic intrinsic clearance increased. FaFg was markedly reduced when the hepatic intrinsic clearance was more than 100 mL W min W kg. This in vivo intrinsic clearance corresponds to an in vitro intrinsic clearance of 78 mL W min W mg human hepatic microsomal protein, equivalent to a half-life of 8.9 min for the substrate in a commonly used metabolic stability test with human microsomes (1 mgMs protein W mL). This phenomenon was not observed in substrates of CYP isoforms other than CYP3A4.
Introduction
When given orally, a drug is absorbed from the gut to enter the systemic circulation via the liver. The fraction of the administered drug reaching the blood circulation is its bioavailability (F), and this is expressed by the product of the fraction absorbed (Fa), intestinal availability (Fg), and hepatic availability (Fh). Although it was thought that Fa and Fh predominantly contributed to F, Fg has been observed to make a signiˆcant contribution in the case of some CYP3A4 substrates such as cyclosporine, midazolam, sirolimus and nifedipine [1] [2] [3] [4] and it has been pointed out that some CYP3A4 substrates exhibit intestinalˆrst-pass metabolism. Not only CYP3A4 but also P-glycoprotein (P-gp) is present in the small intestine acting as an eOEux pump for drugs, and presenting a barrier to drug absorption. 5, 6) It is not so obvious which form of CYP3A4 or P-gp plays a role in low bioavailability because of the overlapping substrate speciˆcity of CYP3A4 and P-gp. 7) Benet et al. have proposed that the synergistic eŠects of CYP3A4-mediated metabolism and P-gp-mediated eOEux in the intestine may result in an unexpectedly highˆrst-pass metabolism. 8, 9) There might be great individual diŠer-ences in the pharmacokinetics of a drug which is metabolized by a pathway exhibiting an intestinalˆrst-pass eŠect. In addition, there is the possibility of severe drug-drug interactions when an inhibitor or inducer is co-administrated because not only hepatic CYP3A4 but also intestinal CYP3A4 is inhibited or induced by the inhibitor or inducer. Therefore, characterization of the intestinalˆrst-pass metabolism is important. For this reason, we have collected information on the pharmacokinetics of CYP3A4 substrates to investigate intestinalˆrst-pass metabolism.
Lin et al. have highlighted a number of problems associated with the estimation of intestinalˆrst-pass metabolism. 10) One problem is that Fg is estimated indirectly under the assumption that the drug is systemically metabolized in the liver only and Fa is 1. 10) In addition, it has been pointed out that Fg is in‰uenced by the rate of hepatic blood ‰ow (Qh). Fg is obtained by dividing F by Fh.
10) The hepatic clearance (CLh) and hepatic blood ‰ow rate are needed to calculate Fh. In the case where CLh＝600 mL W min, F＝0.5 and Qh＝ 1200 mL W min, the Fg value is 1. For Qh＝1600 mL W min, the Fg value is 0.8. So, Fg depends on Qh. Therefore, in the present studies, Fg and Fh can be calculated using three Qh values. P-gp and non-P-gp substrates were selected to examine the synergistic eŠects of CYP3A4-mediated metabolism and P-gp-mediated eOEux in the intestine. We hypothesized that the CYP3A4 substrates which are metabolized well by CYP3A4 in the liver might be extensively metabolized by CYP3A4 in the intestine. It is expected that the FaFg and Fh of non-P-gp substrates are correlated and that those of P-gp substrates do notˆt this relationship due to the eŠect of eOEux in the small intestine if the CYP3A4 activity in the liver and the small intestine is at a certain level because both Fh and Fg are the functions depending on the intrinsic clearance.
Methods
The collection of pharmacokinetic parameters: CYP3A4 substrates that are substrates or non-substrates of P-gp were selected. Cyclosporine, 7, 12) indinavir, 11) nicardipine, 7) quinidine, 12) tacrolimus, 7) and verapamil, 7, 12) were selected as P-gp substrates. Felodipine, 13) midazolam, 14) nifedipine, 7, 14) and propafenone 15) were selected as non-Pgp substrates. The total body clearance (CLtot), renal clearance (CLr), distribution volume (Vd), elimination rate constant and F of these CYP3A4 substrates were obtained from the published literature. The CLtot or ke values of CYP3A4 substrates following co-administration of an inhibitor or inducer were obtained. 1, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] The phramacokinetic data for propafenone in poor metabolizers of CYP2D6 were used because propafenone is mainly metabolized by CYP2D6 and CYP3A4. The Fg of triazolam 29) and zolpidem 30) was used to clarify the eŠect of enzyme induction. The pharmacokinetic parameters of CYP1A, 2C, 2D and 3A substrates were obtained from Goodman and Gilman's textbook, The Pharmacological Basis of Therapeutics, 9th ed.
18)
Analysis: Total body clearances were calculated from the AUC after intravenous administration using equation 1. The hepatic clearance (CLh) was estimated from the CLtot and CLr using equation 2. Fh was calculated from equation 3.
Three rates (17.1 (1200 mL W min W 70 kg), 21.4 (1500 mL W min W 70 kg), and 25.5 mL W mim W kg) were used as Qh. Fa and Fg were evaluated as FaFg, which is the product of Fa and Fg, because Fa and Fg cannot be separated. FaFg was obtained by dividing F by Fh. CLtot was obtained from equation 5 when there were no pharmacokinetic data on CYP3A4 substrates after intravenous administration during treatment with an inhibitor or inducer.
CLtot＝ke Vd (
The hepatic intrinsic clearance (CLint) of CYP3A4 substrates was calculated from equation 6 using the well-stirred model. 
where fp and Rb are the plasma unbound fraction and blood-to-plasma concentration ratio, respectively.
Results
Hepatic and intestinal availability: The FaFg and Fh of CY3A4 substrates were estimated using three Qh values( Table 1) . The relationship between FaFg and Fh is shown in Fig. 1 . No matter which Qh was used, the FaFg of nicardipine, felodipine, midazolam, cyclosporine, and tacrolimus was 0.5 or less. There was no relationship between FaFg and Fh regardless of the hepatic blood ‰ow rate and P-gp substrates. In the case of co-administration of an inhibitor of CYP3A4, the FaFg of cyclosporine, quinidine, tacrolimus, felodipine and midazolam increased regardless of the Qh. There was no marked diŠerence in the increase in FaFg produced by an inhibitor of CYP3A4 between P-gp and non-P-gp substrates. The FaFg of cyclosporine, tacrolimus, midazolam and nifedipine decreased following treatment with an inducer regardless of the Qh.
The relationship between hepatic intrinsic clearance and FaFg: The relationship between the hepatic intrinsic clearance and FaFg calculated using three hepatic blood rates is shown in Fig. 2 . The FaFg of both P-gp and non-P-gp substrates decreased as the hepatic intrinsic clearance increased regardless of the Qh. The FaFg of CYP3A4 substrates decreased when the hepatic intrinsic clearance exceeded 100 mL W min W kg (Fig. 2  and 3) . The FaFg of CYP1A, 2C and 2D substrates did not decrease as the hepatic intrinsic clearance increased (Fig. 3) .
EŠect of enzyme induction: The relation between FaFg before treatment with rifampicin 600 mg W day and the ratio of FaFg before treatment to that after treatment is shown in Fig. 4 . The data for triazolam and zolpidem, which are CYP3A4 substrates, were added. The smaller the values of FaFg, the greater the eŠect of rifampicin. A negative correlation between FaFg and the ratio of FaFg before treatment with rifampicin to that after treatment was observed except for cyclosporine and tacrolimus. 
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Discussion
A certain Qh value has to be assumed when FaFg is estimated from AUCs after intravenous and oral administration. Some values of Qh have been reported previously such as 1200-1600 mL W min, 31) 1314± 403 mL W min 32) and 25.5 mL W min W kg. 33) The estimated FaFg depends on the Qh. Therefore, three Qh values were used in the present studies. The Fh of CYP3A4 substrates for which the hepatic clearance was more than 8 mL W min W kg was in‰uenced by the Qh (Fig. 1 and Table 1 ) and, therefore, the FaFg of those substrates was also in‰uenced by the Qh (Fig. 1 and Table 1 ). The FaFg of nicardipine, felodipine, midazolam, cyclosporine and tacrolimus was less than 0.5 at all the hepatic blood ‰ow rates. If the Fa of these substrates of CYP3A4 can be obtained, it is possible to estimate their intestinalˆrst-pass metabolism. Nicardipine, felodipine and nifedipine were completely absorbed in animal studies and human studies using labeled compounds. [34] [35] [36] The FaFg of felodipine and midazolam, which are non-P-gp substrates, increased following co-administration of an inhibitor of CYP3A4 ( Table 1) . These results suggest that these substrates may be metabolized by CYP3A4 in the intestine. The FaFg of P-gp substrates such as cyclosporine, tacrolimus, quinidine and verapamil also increased following co-administration of an inhibitor. The change in FaFg of P-gp substrates is not necessarily greater than that of non-P-gp substrates ( Table 1) . Benet et al. have proposed the possibility of highˆrst-pass metabolism due to the synergistic eŠects of CYP3A4 and P-gp. 8, 9) Their proposal was also supported theoretically in our previous study. 37) However, in the present study, no supporting evidence was obtained. This may not necessarily exclude a synergetic eŠect between P-gp and CYP 3A4. It might be due to the good absorption of the substrates selected in the present study. This problem should be examined in future studies.
It is expected that the FaFg and Fh of non-P-gp substrates are correlated and those of P-gp substrates do notˆt this relationship because both Fh and Fg are functions of the intrinsic clearance. However, no signiˆcant correlation between FaFg and Fh was observed ( Fig. 1) . This might be due to the plasma protein binding. Protein binding does not aŠect FaFg although it does aŠect Fh. The intrinsic clearance is a value corrected by the plasma unbound fraction. The FaFg of CYP3A4 substrates decreased as the hepatic intrinsic clearance increased (Fig. 2) . This result suggests that a drug which is metabolized well in the liver may also be extensively metabolized in the intestine. The cDNA sequence of CYP3A4 obtained from the intestine was the same as that from the liver 38) and the CYP3A4 in the liver and intestine might be the same protein. In addition, the Km values of CYP3A4 for some substrates in liver and intestine were similar. 2, 39) Therefore, the ratio of the CYP3A4 content in the liver to that in the intestine can be considered to be the ratio of the intrinsic clearance between liver and intestine for CYP3A4 substrates. This reasonably explains the relationship between the hepatic intrinsic clearance and FaFg. The hepatic intrinsic clearance 100 mL W min W kg can be useful as an index of substantial intestinalˆrst-pass metabolism because FaFg was markedly decreased when the hepatic intrinsic clearance was more than 100 mL W min W kg (Fig. 2) . We investigated the relationship between the intrinsic clearance and the FaFg of other CYPs substrates such as CYP 1A, 2C and 2D. The FaFg of these substrates did not decrease as the intrinsic clearance increased (Fig. 3) . It has been reported that approximately 70z of the total CYP in the small intestine is CYP3A4. 40) CYP3A substrates, in particular, might be metabolized in the small intestine. For this reason we proposed a hepatic intrinsic clearance of 100 mL W min W kg as an index of substantial intestinalˆrst-pass metabolism. The human liver weight, microsome content and body weight were assumed to be 1700 g, 52.5 mg W g liver and 70 kg, respectively. The intrinsic clearance 100 mL W min W kg corresponds to 78 mL W min W mg microsomal protein (1275 mg microsomal protein W kg B.W.). When the elimination rate constant is measured using human microsomes, 1 mg W mL, in a metabolic stability test, the hepatic intrinsic clearance 100 mL W min W kg corresponds to 0.078 min -1 . The half-life is 8.9 min (＝0.693 W 0.078). When the elimination half-life of the substrate exceeds 10 minutes in that metabolic stability test using human liver microsomes, the possibility of a substantial degree of intestinalˆrst-pass metabolism may be excluded. When the elimination half-life of the substrate is less than 10 minutes, the compound might be metabolized by CYP3A4 and exhibit low bioavailability.
Although rifampicin induces CYP3A4, it also induces P-gp.
41) The contents of P-gp and CYP3A4 in biopsy samples after treatment with rifampicin, 600 mg W day, measured by Western blotting increased 3.5-and 4.4-fold compared with the values before treatment. 42) It cannot be denied that the decrease in the FaFg of P-gp substrates may be due to the induction of P-gp. However, a decrease in the FaFg of non-P-gp substrates such as midazolam and nifedipine was observed. This result suggests that the decrease in FaFg may be due to the induction of CYP3A4. As shown in Fig. 4 , compounds with low FaFg values are aŠected by treatment with rifampicin 600 mg W day. The phenomenon that the P-gp substrate was aŠected to a greater extent by enzyme induction was not observed. The behavior of cyclosporine and tacrolimus diŠers from that of other CYP3A4 substrates. There could be a number of reasons for this. The FaFg of cyclosporine and tacrolimus was 0.635 and 0.312, respectively, even when ketoconazole was co-administered. The changes in FaFg for cyclosporine and tacrolimus were smaller than those for other substrates, suggesting that Fa might be low. On the other hand, the increase in the hepatic intrinsic clearance of cyclosporine and tacrolimus produced by rifampicin was about 1.5-fold while the increase in the hepatic intrinsic clearance of quinidine and triazolam was about 3-to 4-fold. The low induction eŠect of rifampicin may be one reason. The present study indicates that the intestinalˆrst-pass metabolism of substrates which are metabolized by CYP3A4 in the intestine may be in‰uenced by enzyme induction in the intestine. In the present study, three Qh values were used. A suitable Qh for pharmacokinetic analysis remains to be established. When the hepatic intrinsic clearance of CYP3A4 substrates was estimated using 25.5 mL W min W kg as the Qh, the increase in the hepatic intrinsic clearance of CYP3A4 substrates was approximately 3-to 4-fold. However, when using values of 21.4 or 17.1 mL W min W kg, the increase in hepatic intrinsic clearance was diŠerent for each substrate. A suitable hepatic blood ‰ow rate may be in the region of 25.5 mL W min W kg.
The present study indicates that the CYP3A4 substrates which are metabolized extensively in the liver might also undergoˆrst-pass intestinal metabolism and that the eŠect of P-gp on intestinalˆrst-pass metabolism may be low. On the other hand, Lorn et al. have reported that for peak blood concentrations of cyclosporine, hepatic CYP3A4 activity accounted for 32z and P-gp accounted for 30z of the variability. 43) Thus, P-gp does have an eŠect. As shown in Fig. 2 , the FaFg of cyclosporine tended to be lower than that of other substrates. The tendency towards a low FaFg may be due to P-gp. Ito et al. showed theoretically that the eŠect of P-gp on Fg was small when the eOEux clearance by P-gp was smaller than the sum of the metabolic clearance and absorption clearance by passive diŠusion. 37) A conclusion about the in‰uence of P-gp cannot be drawn from the present study alone because the metabolic and eOEux clearances of each substrate could not be compared. The drugs that exhibit intestinalˆrst-pass metabolism may be easily in‰uenced by an inhibitor or inducer and cause severe drug-drug interactions involving adverse eŠects and lack of e‹cacy. It is preferable to select a candidate that exhibits no intestinalˆrst-pass metabolism during the drug discovery and development process. So far, no quantitative predictions of intestinal rst-pass metabolism are possible. The use of hepatic intrinsic clearance 100 mL W min W kg (the half-life of 8.9 min for a CYP3A4 substrate in the metabolic stability test using 1 mg human Ms protein W mL) is thus proposed. This value can be useful as an index of intestinalˆrst-pass metabolism.
